Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Early detection and accurate diagnosis are pivotal for effective treatment and improved survival rates. Among the advanced diagnostic tools available, the Lung Cancer Panel 6 EGFR by Sequencing, ALK by IHC, ROS1 by FISH Test stands out as a comprehensive approach to identifying specific genetic mutations associated with lung cancer. Offered by DNA Labs UAE, this panel facilitates targeted therapy decisions, providing hope for patients and their families.
Understanding the Symptoms of Lung Cancer
Lung cancer often goes undetected in its early stages as it may not present any symptoms or the symptoms might mimic those of other common respiratory conditions. However, recognizing the potential signs of lung cancer is crucial for early diagnosis. Symptoms may include persistent coughing, changes in cough pattern or color of sputum, shortness of breath, chest pain, unexplained weight loss, fatigue, and recurrent respiratory infections. It is important to consult a healthcare professional if you experience any of these symptoms, especially if you are at a higher risk of lung cancer.
Importance of Genetic Testing in Lung Cancer
Genetic testing plays a vital role in the diagnosis and management of lung cancer. It helps in identifying specific genetic mutations that may drive the growth of cancer cells. These mutations can be targeted by specific drugs, making treatment more effective and personalized. The Lung Cancer Panel 6 test offered by DNA Labs UAE is designed to detect mutations in the EGFR gene by sequencing, ALK rearrangements by Immunohistochemistry (IHC), and ROS1 rearrangements by Fluorescence In Situ Hybridization (FISH). Identifying these mutations is crucial for selecting the most appropriate targeted therapy for patients with non-small cell lung cancer (NSCLC).
Components of the Lung Cancer Panel 6 Test
- EGFR by Sequencing: This test identifies mutations in the EGFR gene, which are present in approximately 10-15% of NSCLC patients in the US and Europe, and up to 50% in Asian countries. EGFR mutations are associated with sensitivity to EGFR tyrosine kinase inhibitors.
- ALK by IHC: ALK rearrangements are found in 3-7% of NSCLC patients. The ALK by IHC test is used to detect these rearrangements, which predict responsiveness to ALK inhibitors.
- ROS1 by FISH: ROS1 rearrangements are present in 1-2% of NSCLC patients. The ROS1 by FISH test identifies these rearrangements, indicating potential benefit from ROS1 inhibitors.
Test Cost and Accessibility
The Lung Cancer Panel 6 test is available at DNA Labs UAE for 6000 AED. While the cost may seem significant, it is an investment in a potentially life-saving diagnosis that can lead to more effective and personalized treatment options. Early detection and precise targeting of genetic mutations can significantly improve outcomes for lung cancer patients.
Conclusion
Lung cancer diagnosis and treatment have evolved significantly with the advent of genetic testing. The Lung Cancer Panel 6 EGFR by Sequencing, ALK by IHC, ROS1 by FISH Test offered by DNA Labs UAE represents a cutting-edge approach to identifying specific genetic mutations associated with lung cancer. By enabling targeted therapy, this test opens new avenues for personalized medicine, offering hope for better treatment outcomes. For more information and to access this test, visit DNA Labs UAE.
